The clinical impact of pharmacogenomics remains a hot topic of current research efforts. Although pharmacogenomics of phase I metabolizing enzymes seems to have been well studied, knowledge on the clinical impact of genetic variability of phase II metabolizing enzymes and drug transporters is more limited. This paper reviews data on the pharmacogenomics of phase II metabolizing enzymes as well as of ATP binding cassette transporters and of solute carrier transporters focusing on clinical implications for drug efficacy and drug toxicity. The clinical impact of some of these polymorphisms has been well defined i.e. the association between polymorphisms of organic anion transporter polypeptides and statin induced myopathy. However, as the same drug may be substrate for different enzymes and different transporters, it is difficult to elucidate the impact of each polymorphism. Investigating the impact of multiple polymorphisms might be more clinically meaningful, although methodologically challenging.
INTRODUCTION
Pharmacogenomics investigates interindividual genetic variability in DNA sequence of drug targets, drug metabolizing enzymes, drug transporters or disease genes, RNA expression, or protein translation of genes affecting drug response and drug safety. 1 Thus, the clinical impact of pharmacogenomics remains a hot topic of current research efforts. Although the clinical impact of pharmacogenomics of phase I metabolizing enzymes seems to be well defined in many cases, knowledge on the clinical impact of genetic variability of phase II metabolizing enzymes and transporters is more limited. This paper aims to review data on the clinical implications of pharmacogenomics of phase II metabolizing enzymes and of drug transporters (Tables 1 and 2 ).
PHARMACOGENOMICS OF PHASE II DRUG METABOLIZING ENZYMES
Phase II enzymes conjugate phase I metabolites, other intermediates, or the parent compound for renal or biliary excretion. Phase II enzymes include glutathione S transferases (GSTs), thiopurine-Smethyltransferase (TMPT), UDP glycurosyltransferases (UGT), N-acetyltransferases, (NAT), glutathione S transferases GSTs, NADH quinone oxidases and others. Defective alleles for N-acetyltransferase -2 are responsible for the acetylation polymorphism that leads to impaired clearance and hepatotoxicity of isoniazid. 2 GSTs contribute to the detoxification of chemotherapeutic agents and genetic variations in GSTs genes have been associated with increased chemotherapeutic treatment benefit in colorectal cancer patients.
TMPT metabolizes thiopurine drugs such as mercaptopurine, azathioprine and thioguanine, that are prodrugs used in the treatment of acute lymphoblastic anaemia, autoimmune disorders and inflammatory bowel disease. TMPT catalyzes the S methylation of these prodrugs into inactive metabolites. Polymorphisms of the TMPT gene affect enzyme activity. An elevated risk of severe or even fatal myelosuppression is observed in TMPT deficient patients treated with thiopurine drugs. [3] [4] [5] [6] Genotyping for the common TMPT alleles is recommended as it can identify patients at risk for toxicity. 7, 8 However, although there is a strong phenotype-genotype association for TMPT, most of the thiopurine induced adverse reactions and the efficacy of therapy cannot be explained by TMPT polymorphisms.
UGTs catalyze the glucoronidation of many lipophilic xenobiotics and endobiotics to make them more water soluble and therefore enhance their elimination. UGTs are quite important for the metabolism of psychiatric drugs including some antipsychotics, some antidepressants, some mood stabilizers and some benzodiazepines. Overall, polymorphisms of UGTs have not been investigated adequately due to the overlapping activities of the UGTs and the lack of selective probes, due to the complexity of the glucuronidation cycle and due to the difficulty of developing analytic methods to measure glucuronides. Variation in drug metabolism due to altered UGT activity as a consequence of polymorphisms has been described for UGT1A1 and UGT2B7.
The chemotherapeutic agent irinotecan is a camptothecin derivative, that is converted to its active metabolite SN-38 by carboxylesterases enzymes in the liver with SN-38 being subsequently conjugated primarily by UGT1A1 for elimination in bile and urine. 9 The main dose-limiting toxicities of irinotecan are myelosuppression and delayed type diarrhea and are attributed to increased levels of the active metabolite SN-38. 10 Reduced expression of UGT1A1 due to polymorphisms of the gene is associated with lower SN-38 glucuronidation and increased incidence of toxicity. In 2004, a small clinical study showed that the homozygous UGT1A1*28 genotype was associated with an increased risk of severe neutropenia and severe delayed type diarrhea. In 2005, the FDA suggested a reduction by at least one level in the starting dose of irinotecan for patients homozygous for the UGT1A1*28 allele. However, there is no clear recommendation on the necessity of screening patients for UGT1A1*28 allele before the administration of irinotecan. 3, 6, 7, 10 UGT2B7 polymorphisms have been associated with diclofenac induced hepatotoxicity. 11 A recent study has suggested a potential role of UGT2B17 deletion in the metabolism of exemestane, a third generation aromatase inhibitor used in the treatment of breast cancer in postmenopausal women. Reduction to form 17-dihydroxyexemestane and subsequent glucuronidation to exemestane-17-O-glucuronide is a major pathway for exemestane metabolism. Literature data suggest that UGT2B17 deletion polymorphism might play a role in exemestane metabolism. 12 
DRUG TRANSPORTERS
Transporters are integral membrane proteins that mediate the translocation of chemicals into and out of cells using active and passive mechanisms. 13 Transporters can be classified as influx or efflux transporters which are located either at the basolateral or apical membrane in polarized cells.
14 Efflux transporters include ATP binding cassette transporter family (ABC) and multidrug toxin extrusion proteins (MATES). 15 Influx transporters are the organic anion transporters (OATs and OATPs), organic cation transporters (OATPs) and oligopeptide transporters. Besides physiological substances, drugs are also substrates for some transporters. Interplay of influx and efflux transporters with phase I and phase II metabolism enzymes is required for the sequential traverse of the basolateral and apical membranes. 16 For example, in the liver, an uptake transporter as the organic anion transporter polypeptide B1 (OATPB1) may extract its drug substrates from the portal blood into hepatocytes. After metabolism, other transporters such as MDR1 may be important for efflux of the metabolites from the hepatocytes. 17 Transporters affect absorption, tissue distribution and elimination of drugs. In addition, transporters are implicated in the determination of the concentrations of drugs in plasma and peripheral tissues, thus affecting drug efficacy and toxicity. 18 Polymorphisms especially single nucleotide polymorphisms are commonly encountered in transporters and some of these have substantial impact in their activity. The effect of these polymorphisms on pharmacokinetics of drugs may have clinical implications especially for drugs with narrow therapeutic index and interpatient and intra-patient variability. 19 Functional genomic studies have been conducted focusing on nonsynonymous polymorphisms of drug transporters. The main findings of these studies have been summarized as follows: nonsynonymous SNPs that alter function may affect the interactions of substrates and inhibitors with the transporter, but generally appear to affect the expression level of the transporter on the plasma membrane through changes in protein stability, subcellular localization or membrane trafficking; some nonsynonymous SNPs may result in substrate-dependent changes in transporter function; rare nonsynonymous variants (minor allele frequency o1%) are more likely to exhibit reduced function than common nonsynonymous variants; Multiple variants in a single transporter may result in reduced function. 20 
ATP BINDING CASSETTE (ABC) TRANSPORTERS
Transporters concerned with outward drug transport are mainly members of the ATP-dependent ABC transporter (ATP-bindingcassette transporter) family, the largest family of transmembrane proteins that bind ATP and use the energy to transport various substances over cell membranes. These transporters are classified into seven families (ABCA to ABCG) based on the nucleotide binding domain and the transmembrane domains. 21 ABC transporters are found in tissue barriers and excretory organs where they efflux substances from an organ or the body against a concentration gradient (e.g. excretion into bile). Due to their role in the efflux of chemotherapeutic and other drugs from their target cells, they were known as multidrug resistance transporters (MDRs). There are at least 49 ABC transporter genes, but mainly ABCB1, ABCC1, ABCC2, ABCC3 and ABCG2 are involved in drug transport. 19 The human ABCB1 (MDR1) gene located on chromosome 7q21 is composed of 29 exons. More than 50 SNPs and other polymorphisms affect the function of the well characterized ABCB1 gene encoding the transporter P-glycoprotein (P-gp). P-gp substrates include toxic xenobiotics and numerous commonly used medications i.e. chemotherapeutic agents including anthracyclines, vinca alkaloids, taxanes, and etoposide; tyrosine kinase inhibitors such as imatinib, nilotinib and dasatinib; HIV protease inhibitors and HMG-CoA inhibitors.
22,23 P glycoprotein is expressed in liver, kidney, intestine and the endothelial cells of the blood brain barrier.
22,23 P-gp protects cells against toxins, whereas P-gp confers multi-drug resistance phenotype in malignant cells. A synonymous SNP in exon 27 (C3435T) was the first variant to be associated with altered expression in the human gastrointestinal tract, although the SNP does not change the encoded amino acid. Pgp expression in the duodenum of individuals with the CC genotype was two fold higher when compared with that in individuals with the TT genotype and was associated with significantly decreased plasma concentrations of the Pgp substrate digoxin after oral administration, suggesting that digoxin absorption was lower in individuals with high Pgp levels. 24 However, following relevant studies had discordant results.
Clopidogrel is a P-gp substrate and inhibition of P-gp has been shown to influence the bioavailability of clopidogrel. In addition it has been suggested that individuals with genetic variants in ABCB1 (specifically those who are TT homozygotes for the C3435T variant) when treated with clopidogrel, have lower levels of the active drug metabolite, and thus may have higher rates of adverse clinical outcomes. A relevant study based on a nationwide French registry demonstrated that among patients presenting with myocardial infarction and receiving clopidogrel, the carriers of two variant alleles 3435C-T had a higher rate of cardiovascular events (death from any cause, nonfatal stroke, or myocardial infarction) at 1 year than those with the ABCB1 wild-type genotype. 25 In another study, an increased risk of recurrent ischemic attacks has been noted in carriers of two variant alleles 3435C-T treated with clopidogrel. 26 In addition, it has been shown that healthy volunteers carrying the ABCB1 3435C4T have reduced maximum platelet aggregation under clopidogrel, 26 although these results have not been replicated in a subsequent study. According to existing data, CYP2C19 polymorphisms seem to be more relevant in the effect of clopidogrel treatment. 27 Currently, ABCB1 genotyping is not recommended for predicting responsiveness to clopidogrel. 28 In fact, the effect of ABCB1 polymorphisms on drug disposition and drug efficacy has not been clarified, because of the following reasons: high genetic variation of ABCB1 in different populations; variability in a given SNP influences its expression/function in different organs; there are compensatory transporters; its expression in multiple organs affects biological processes involved in absorption, distribution, elimination, enterohepatic circulation; ABCB1 transports a great number of substrates; in addition, physiology and disease influence drug transport.
29 ABCB1 polymorphisms have also been implicated in drug safety with ABCB1 SNPs being associated with taxane induced neutropenia and peripheral neuropathy. 30 In addition, polymorphisms have been reported for other members of the ABC family, but their clinical significance has not been elucidated. The G subfamily of ABC transporters consists of half-transporters, which oligomerise to form the functional transporter. ABCG1, ABCG4 and ABCG5/8 are involved in the ATPdependent translocation of steroids and other lipids. 31 ABCG2, breast cancer resistance protein (BCRP,) is an ABC transporter whose overexpression has been associated with high levels of resistance to a variety of anticancer agents, including anthracyclines, mitoxantrone, and the camptothecins, by enhancing drug efflux. 32 BCRP substrates include chemotherapeutic agents such as mitoxantrone, methotrexate, topotecan, irinotecan and its active analog SN-38, and tyrosine kinase inhibitors imatinib and gefitinib, but also other drugs such as prazosin, glyburide, nitrofurantoin, dipyridamole, statins, and cimetidine as well as non-therapeutic compounds such as the dietary flavonoids, porphyrins, estrone 3-sulfate (E 1 S), and the carcinogen PhIP. 32 In addition, it has been demonstrated that subjects with reduced BCRP are at increased risk for gefitinib induced diarrhea, an inhibitor of the epidermal growth factor receptor tyrosine kinase with activity in non small cell lung cancer. 33 The ABCC family includes the multidrug resistance associated proteins MRP1/ABCC1, MRP2/ABCC2, MRP3/ABCC3, MRP4/ABCC4, MRP5/ABCC5, MRP6/ABCC6, MRP7/ABCC10, MRP8/ABCC11 and MRP9/ABCC12. The human MRP/ABCC transporters except MRP9/ ABCC12 transport organic anions, such as drugs conjugated to glutathione, sulphate or glucuronate. 34 The SNP (538 G4A) of the ABCC11 gene has been suggested to be a clinical biomarker for prediction of chemotherapeutic efficacy to methotrexate treatment. 35 The ABCC1 transporter is responsible for the efflux of SN-38 from the hepatocyte into the interstitial space. 36 Rare variants of ABCC1 affect transport function, but their low allele frequency precludes a major role in human drug disposition. [36] [37] [38] [39] [40] Evidence suggests that an ABCC2 haplotype may predict irinotecan toxicity in patients who are not carriers of UGT1A1*28.
41 ABCC2 is involved in biliary excretion of diclofenac and ABCC2 polymorphisms have been associated with diclofenac induced hepatotoxicity. 11 SNPs of ABCC5 and ABCG1 have been associated with irinotecan associated gastrointestinal toxicity in colorectal cancer patients in a genetic screening study using the Affymetrix DMET Plus Assay. 42 
SOLUTE CARRIER TRANSPORTERS
Solute carrier transporters (SLC) are found throughout the body and play significant role in cellular homeostasis and distribution of nutrients. SLC transporters consist of channels, facilitated transporters and active transporters and are classified into two superfamilies including 40 families. The superfamilies of solute carriers with importance in drug disposition are SLC22A (organic cation transporters OCTs and organic anion transporters OATs), and SLCO (organic anion transporting polypeptides OATPs) formerly (SLC21A superfamily). 43 OATs transport the smaller and more hydrophilic organic anions while OATPs transport the large and hydrophobic anions. 43 
ORGANIC ANION TRANSPORTING POLYPEPTIDES
Genes encoding organic anion transporting polypeptides form a large family of solute carrier organic anion transporter genes (SLCO). OATPs have been classified in families characterized by an Arabic numerical. The SLCO1 family is the largest human family including the genes encoding OATP1A2, OATP1B1, OATP1B3, and OATP1C1. 18 So far, there is no crystal structure available for any of the OATPs. Putative three dimensional models of OATPs have been constructed through molecular modelling. Based on these models, OATPs are predicted to contain 12 transmembrane domains with both termini located intracellularly. 43 The drug transporters of the SLCO/OATP family are mainly concerned with the inward transport of drugs into cells like hepatocytes and renal tubular cells. OATP-mediated uptake into the hepatocyte coupled with subsequent excretion into bile via efflux proteins, such as MRP2, is often referred to as hepatobiliary excretion. 44 The family's natural substrates include bile salts, thyroid hormones, prostaglandins. Some of the forms also transport benzylopenicillin and statins. In vitro SLCO1B1 (OATP1B1) drug substrates include several HMG-CoA reductase inhibitors, or statins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, antidiabetic drug repaglinide, and the anticancer drugs methotrexate and irinotecan. SLCO1B1 is a key mechanism in the transport of pravastatin, rosuvastatin, pitavastatin, simvastatin, fluvastatin, atorvastatin, lovastatin and cerivastatin across the hepatic sinusoidal membrane with greater significance for hydrophilic statins. 18 However, some statins, such as fluvastatin and rosuvastatin are also substrates of other OATPs. 18 Sixteen SNPs have been described for SLCO1B1.
18
A non synonymous polymorphism in SLCO1B1 (coding DNA c.521 T4C, protein p.V174A, rs4 149 056) has been associated with the pharmacokinetics of several widely prescribed drugs. These include some but not all statins ie. fluvastatin and this polymorphism may be also associated with adverse drug reactions of statins. This polymorphism decreases the ability of OATPB1 to transport active simvastatin and other statins from the portal circulation resulting in markedly increased plasma concentration of statin and thus enhancing the risk of statin induced myopathy and reducing the therapeutic index of statins.
14,18 SLCO1B1 polymorphisms also affect the pharmacokinetics of the antihistamine fexofenadine, of the endothelin A receptor antagonist atrasentan and of the antidiabetic drug repaglinide.
14 Thus, the SLCO1B1 c.521CC genotype has been associated with an about 60-190% increased, and the SLCO1B1*1B/*1B genotype with an about 30% decreased area under the plasma concentration-time curve of repaglinide.
14 SLCO1B1 genotype may affect the pharmacokinetics of ezetimibe glucuronide. In addition, the SLCO1B1*15 haplotype (or 521 T4C genotype) results in decreased uptake activity of the metabolite of irinotecan, SN-38, from systemic circulation, leading to increased plasma concentration of SN-38 and an enhanced risk of neutropenia. Moreover, certain SLCO1B1 variants associated with an enhanced clearance of methotrexate increase the risk of gastrointestinal toxicity by methotrexate in the treatment of children with acute lymphoblastic leukemia. 18 Evidence on the clinical significance of polymorphisms of other OATPs is limited. It has been showed that OATP1A2 polymorphisms are associated with imatinib clearance. 45 Polymorphisms of OATP2B1 have been associated with pharmacokinetics of fexofenadine. 46 
ORGANIC ANION TRANSPORTING POLYPEPTIDES AND STATIN INDUCED MYOPATHY
Solute carrier transporter pharmacogenomics has been implicated in a number of adverse drug reactions, encompassing chemotherapeutic agents and statins. In particular, as already mentioned, statins can cause myopathy. The incidence of myopathy is 1/ 10 000 patients (for standard doses 20-40 mg of simvastatin), but increases for higher doses (e.g. 80 mg of simvastatin). Statin induced muscle toxicity caused by statins most commonly manifests as an asymptomatic increase of CPK levels and in the most severe cases can cause rhabdomyolysis and death. The mechanism of muscle damage is unclear and various hypotheses have been proposed, including a recent one, according to which, atrogin 1, a gene involved in muscle atrophy, is involved in the pathogenesis of statin induced toxicity. Various candidate gene studies have been performed, but most findings either have shown a low odds ratio, or have not been replicated. Recently, a genome wide association study of subjects on 80 mg of simvastatin showed a strong association of simvastatin induced myopathy with the organic anion transporter protein B1 OATPB1, transporter gene SLCO1B1 and in particular with the noncoding SNP OATP1B1*5 (rs4 363 657). This polymorphism reduces hepatic transport of simvastatin with subsequent increase of plasma concentrations of the drug. This result was subsequently replicated in a study of 16 644 persons on lower doses of simvastain (40 mg). 47 Moreover, it is not known if it is a drug effect or a class effect. Thus, in a recent study investigating severe statin associated myopathy in a cohort of patients using various statin medications, the SLCO1B1 rs4 363 657 genotype was not significantly associated with myopathy in patients treated with atorvastatin. In addition, CYP polymorphisms have been implicated in statin induced rhabdomyolysis.
ORGANIC ANION TRANSPORTERS
Organic anion transporters 1-10 (OAT 1-10) are predicted to be transmembrane proteins with 12 domains and both termini intracellularly. No crystallographic structure has been described for OATs 43 . OAT1 and OAT3 are located in the basolateral membrane of renal proximal tubule cells and are responsible for drug uptake from the blood into the cells. OAT4 is located in the apical membrane of human proximal tubule cells and has been related to drug exit into the lumen and uptake of estrone sulfate and urate from the lumen into the cell. Extarenal locations of OATs include the blood brain barrier, the placenta, the nasal epithelium and the liver 48 . SNPs have been described for OATPs. Clinical studies have investigated the impact of non synonymous polymorphisms in coding regions of OATs and have demonstrated that only a few have an effect on transporter function. However, the role of synonymous SNPs and the role of non synonymous SNPs in non coding regions has not been investigated. Furthermore, it is estimated that unidentified SNPs may also exist. 49 
ORGANIC CATION TRANSPORTERS
The organic cation transporter (OCT) family contains three subtypes of facilitated transporters called OCT1 (encoded by the SLC22A1 gene), OCT2 (SLC22A2), and OCT3 (SLC22A3).
49 OCT1 (SLC22A1) and OCT2 (SLC22A2) seem to be restricted mainly to excretory organs such as the liver and kidney, OCT3 (SLC22A3) shows a much broader tissue distribution, including skeletal muscle, heart, brain and placenta. OCT substrates include the oral antiherglycemic drug metformin, the histamine receptor antagonist cimetidine and antivirals such as acyclovir. 43 Endogenous substrates of OCTs include acetycholine and catecholamines. It has been suggested that organic cation transporters, OCT1 and OCT2, play a critical role in the disposition and response to metformin and that genetic variants of these transporters are associated with variation in pharmacokinetics and anti-diabetic activity of the drug. 43 In addition, coding region polymorphisms in these genes have been associated with cisplatin-induced nephrotoxicity and ototoxicity. 50 
CONCLUSION
Current evidence suggests that pharmacogenomics of phase II metabolizing enzymes and drug transporters has clinical implications for drug safety and drug efficacy. However, as the same drug may be substrate for different enzymes and different transporters, it is difficult to elucidate the impact of each polymorphism. Investigating the impact of multiple polymorphisms might be more clinically meaningful, although methodologically challenging. In addition, clinical validation could be facilitated by incorporating pharmacogenomics in the design of phase II clinical trials.
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